NYSEAMERICAN:BPMX

Biopharmx Stock Forecast, Price & News

$1.31
+0.04 (+3.15 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.26
$1.34
50-Day Range N/A
52-Week Range
$0.25
$1.18
Volume1.33 million shs
Average Volume2.15 million shs
Market Capitalization$23.94 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BPMX News and Ratings via Email

Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter.


Biopharmx logo

About Biopharmx

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.62 out of 5 stars

Medical Sector

1402nd out of 2,096 stocks

Biotechnology Industry

16th out of 89 stocks

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Biopharmx (NYSEAMERICAN:BPMX) Frequently Asked Questions

What stocks does MarketBeat like better than Biopharmx?

Wall Street analysts have given Biopharmx a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biopharmx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Biopharmx's earnings last quarter?

Biopharmx Corp (NYSEAMERICAN:BPMX) issued its quarterly earnings results on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.64) by $0.96.
View Biopharmx's earnings history
.

When did Biopharmx's stock split? How did Biopharmx's stock split work?

Biopharmx shares reverse split before market open on Tuesday, May 19th 2020. The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of Biopharmx stock prior to the reverse split would have 8 shares after the split.

Who are Biopharmx's key executives?

Biopharmx's management team includes the following people:
  • Dr. David S. Tierney M.D., Pres, CEO, CFO and Director (Age 55)
  • Dr. Kin Foong Chan, Exec. VP of Research & Technology (Age 45)
  • Dr. José Zayas, Sr. VP of Operations
  • Ms. Joyce Goto, VP, Chief Accounting Officer & Controller (Age 45)
  • Ms. AnnaMarie Daniels, Exec. VP of Clinical & Regulatory Affairs

Who are some of Biopharmx's key competitors?

What other stocks do shareholders of Biopharmx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), CytRx (CYTR), Protalix BioTherapeutics (PLX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN).

What is Biopharmx's stock symbol?

Biopharmx trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BPMX."

How do I buy shares of Biopharmx?

Shares of BPMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biopharmx's stock price today?

One share of BPMX stock can currently be purchased for approximately $1.31.

How much money does Biopharmx make?

Biopharmx has a market capitalization of $23.94 million.

How many employees does Biopharmx have?

Biopharmx employs 17 workers across the globe.

What is Biopharmx's official website?

The official website for Biopharmx is www.biopharmx.com.

Where are Biopharmx's headquarters?

Biopharmx is headquartered at 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States.

How can I contact Biopharmx?

Biopharmx's mailing address is 1505 Adams Dr Ste D, MENLO PARK, CA 94025-1451, United States. The biotechnology company can be reached via phone at +1-650-8895020.


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.